Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9395356 | 0.84 | MAPT (0.57) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL8746689 | 0.83 | ALDH1A1 (0.54) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL8746687 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL18690302 | 0.80 | MAPT (0.47) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL10741564 | 0.79 | IDO1 (0.54) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL3646086 | 0.79 | MAPT (0.51) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL2026375 | 0.79 | MAPT (0.51) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL11270645 | 0.79 | ALDH1A1 (0.51) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL10652156 | 0.79 | MAPT (0.55) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL7297643 | 0.78 | MAPT (0.58) | ALDH1A1MAPTPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1953 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605310-B | Synthesis method of aza five-membered ring and three-membered ring carboxylic ester derivative and salt thereof | 都创(上海)医药科技股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| EP-3838890-B1 | METHOD FOR PREPARING 18F-BPA AND INTERMEDIATE | NEUBORON MEDTECH LTD (CN) | 2023-10-04 | — | — | EP | claimed |
| US-20230242555-A1 | METHOD FOR PREPARING 18F-BPA AND INTERMEDIATE | NEUBORON MEDTECH LTD. (CN) | 2023-08-03 | — | — | US | claimed |
| CN-110835310-B | Intermediate, preparation method and application | 南京中硼联康医疗科技有限公司 | 2022-09-20 | — | — | CN | claimed |
| WO-2022123501-A1 | PROTECTED DEOXYDIDEHYDRO-NUCLEOSIDES | VICTORIA LINK LIMITED (NZ) | 2022-06-16 | — | — | WO | claimed |
| CN-114605310-A | Synthesis method of aza five-membered ring and three-membered ring carboxylate derivative and salt thereof | 都创(上海)医药科技股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-110835352-B | Preparation method18Process for F-BPA | 南京中硼联康医疗科技有限公司 | 2022-05-24 | — | — | CN | claimed |
| CN-114436929-A | Synthesis method of N-protected 3, 4-dehydro-L-proline ester | 都创(重庆)医药科技有限公司 | 2022-05-06 | — | — | CN | claimed |
| US-9714560-B2 | Protected scale inhibitors and methods relating thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-25 | — | — | US | claimed |
| US-9493469-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | claimed |
| WO-2010006954-A1 | NOVEL N-SUBSTITUTED BETA-AMINO ACID ESTERS | DSM IP ASSETS B.V. (NL) | 2010-01-21 | — | — | WO | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240228486-A1 | SULFONE- AND SULFOXIMINE-BASED SELECTIVE PARP1 INHIBITORS | ENLIVEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-4492694-A | ORAL ADMINISTRATION | ELI LILLY AND COMPANY (US) | 1985-01-08 | — | — | US | disclosed |
| US-4482553-A | ANTIBIOTICS, BACTERICIDES | ELI LILLY AND COMPANY (US) | 1984-11-13 | — | — | US | disclosed |
| EP-0122156-A2 | Improvements in or relating to benzothienylglycyl cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1984-10-17 | — | — | EP | disclosed |
| EP-0122157-A2 | Improvements in or relating to indolylglycyl cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | CACNA1E, TRPV1, SCN3A | ALDH1A1 1207/4885MAPT 4372/4885POLB 4728/4885 |
| US-20230242555-A1 | METHOD FOR PREPARING 18F-BPA AND INTERMEDIATE | CYP19A1, SHBG, ESR1 | ALDH1A1 506/4885MAPT 1915/4885POLB 402/4885 |
| US-20240228486-A1 | SULFONE- AND SULFOXIMINE-BASED SELECTIVE PARP1 INHIBITORS | PARP2, PARP1, PARP12 | ALDH1A1 1846/4885MAPT 3531/4885POLB 155/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | ALDH1A1 1555/4885MAPT 3123/4885POLB 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.